These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19785093)

  • 1. NY: Failure to administer TPA to stroke victim: TPA not indicated while in defendants' care. Flanagan v. Catskill Regional Medical Center, 2009-NY-06161 (8/11/2009)-NY.
    Nurs Law Regan Rep; 2009 Aug; 50(3):3. PubMed ID: 19785093
    [No Abstract]   [Full Text] [Related]  

  • 2. Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.
    Weintraub MI
    Stroke; 2006 Jul; 37(7):1917-22. PubMed ID: 16728683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NY: Failure to diagnose & treat VAD: court affirmed judgment for defendants. Helfer v. Chapin, 2012 NY APP3 (6/21/2012)-NY.
    Nurs Law Regan Rep; 2012 Jul; 53(2):3. PubMed ID: 22919779
    [No Abstract]   [Full Text] [Related]  

  • 4. FL: Nurse's notes & records contradict Dr.: court finds for defendants despite nurse's info. St. Joseph's Hospital v. Cox, 2009 FL-0618.068 (6/17/2009)-FL.
    Nurs Law Regan Rep; 2009 Jun; 50(1):3. PubMed ID: 19645204
    [No Abstract]   [Full Text] [Related]  

  • 5. Tissue plasminogen activator for acute ischemic stroke: a New York city emergency medicine perspective.
    Chan YF; Kwiatkowski TG; Rella JG; Rennie WP; Kwon RK; Silverman RA
    J Emerg Med; 2005 Nov; 29(4):405-8. PubMed ID: 16243196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-hospital delays to stroke thrombolysis: paradoxical effect of early arrival.
    Romano JG; Muller N; Merino JG; Forteza AM; Koch S; Rabinstein AA
    Neurol Res; 2007 Oct; 29(7):664-6. PubMed ID: 18173904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a medicolegal approach in clinical stalemates.
    Tang M
    J Med Ethics; 2012 Nov; 38(11):645-6. PubMed ID: 22923440
    [No Abstract]   [Full Text] [Related]  

  • 8. Expectations for tPA is pathway to litigation.
    ED Manag; 2011 Feb; 23(2):18-9. PubMed ID: 21400969
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical Policy: Use of intravenous tPA for the management of acute ischemic stroke in the emergency department.
    ;
    Ann Emerg Med; 2013 Feb; 61(2):225-43. PubMed ID: 23331647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of intravenous tissue plasminogen activator for ischemic stroke: are there sex differences?
    Allen NB; Myers D; Watanabe E; Dostal J; Sama D; Goldstein LB; Lichtman JH
    Cerebrovasc Dis; 2009; 27(3):254-8. PubMed ID: 19176959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When time matters most. Group working on new stroke readiness program.
    Lovern E
    Mod Healthc; 2001 Jun; 31(25):88. PubMed ID: 11436396
    [No Abstract]   [Full Text] [Related]  

  • 12. Early treatment of ischemic stroke with intravenous tPA reduces disability risk.
    Mitka M
    JAMA; 2013 Sep; 310(11):1111. PubMed ID: 24045728
    [No Abstract]   [Full Text] [Related]  

  • 13. Barriers to administering intravenous tissue plasminogen activator (tPA) for acute ischemic stroke in the emergency department: A cross-sectional survey of stroke centers.
    Hargis M; Shah JN; Mazabob J; Rao CV; Suarez JI; Bershad EM
    Clin Neurol Neurosurg; 2015 Aug; 135():79-84. PubMed ID: 26047090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More Time Is Taken to Administer Tissue Plasminogen Activator in Ischemic Stroke Patients with Earlier Presentations.
    Rossi KC; Liang JW; Wilson N; Tuhrim S; Dhamoon MS
    J Stroke Cerebrovasc Dis; 2017 Jan; 26(1):70-73. PubMed ID: 27639586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender Differences in Exclusion Criteria for Recombinant Tissue-Type Plasminogen Activator.
    Fredwall M; Sternberg S; Blackhurst D; Lee A; Leacock R; Nathaniel TI
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2569-2574. PubMed ID: 27618196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
    Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empirical characteristics of litigation involving tissue plasminogen activator and ischemic stroke.
    Liang BA; Zivin JA
    Ann Emerg Med; 2008 Aug; 52(2):160-4. PubMed ID: 18313798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drill down analysis of door-to-needle time of acute ischemic stroke patients treated with intravenous tissue plasminogen activator.
    Schrock JW; Lum M
    Am J Emerg Med; 2014 Nov; 32(11):1330-3. PubMed ID: 25195044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.
    Sahlas DJ; Gould L; Swartz RH; Mohammed N; McNicoll-Whiteman R; Naufal F; Oczkowski W
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):155-9. PubMed ID: 23375748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue Plasminogen Activator Prescription and Administration Errors within a Regional Stroke System.
    Chung LS; Tkach A; Lingenfelter EM; Dehoney SB; Rollo J; de Havenon A; DeWitt LD; Grantz MR; Wang H; Wold JJ; Hannon PM; Weathered NR; Majersik JJ
    J Stroke Cerebrovasc Dis; 2016 Mar; 25(3):565-71. PubMed ID: 26698642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.